Features of moxonidine (physiotens) effect on dialysis stage patients’ with chronic kidney disease cardiovascular system and life quality

Close metadata

OBJECTIVE

To identify the features of the effect of the drug moxonidine (physiotens) on quality of life (QL) indicators, clinical and laboratory parameters of the cardiovascular system (CCS) in patients with terminal CKD.

MATERIAL AND METHODS

The research included 30 patients with AH and CKD of 5D stage (Male/Female — 15/15). The average age was 49±13.1 years. In addition to conventional antihypertensive therapy, all patients were added moxonidine (Physiotense 0.4 mg Abbott Laboratories GmbH, Germany) in the evening for 12 weeks. A number of clinical indicators were monitored, including a study of QL, depression level, BP, ECHO, erythrocyte electrophoretic mobility.

RESULTS

It was found that after the treatment, there was a decrease in predialysis SBP and DBP. According to echo, after treatment, a decrease in left ventricular myocardial mass and index of left ventricular myocardial mass (p<0.01) was revealed, which indicates a decrease in left ventricular hypertrophy. It was obtained that after the use of moxonidine there was an increase in all the scales of the questionnaire, mainly on the scale Total mental component (p<0.01), Increased on the scale Total physical component (p<0.05). There was an increase in Sexual Function (p<0.05), which may indirectly indicate an improvement in endothelial function in patients. A decrease in the severity of symptoms and the frequency of depression (p<0.05) was revealed. Analysis of erythrocyte electrophoretic mobility indices revealed an increase in the average amplitude of erythrocyte fluctuations (AAEF, p<0.01) after therapy. An increase in this parameter shows a possible cytoprotective effect of physiotens.

CONCLUSION

Three-month therapy with moxonidine in AH patients treated with hemodialysis programs effectively reduces BP, improves the structural-functional state of the myocardium, and positively affects the electrophoretic mobility of red blood cells. Patients have improved quality of life and reduced symptoms of depression.

Keywords:

arterial hypertension

moxonidine

chronic kidney disease

quality of life

depression

left ventricular hypertrophy

erythrocyte electrophoretic mobility

program hemodialysis

Authors:

Kazakova I.A.

Izhevsk State Medical Academy

Ievlev E.N.

Izhevsk State Medical Academy

Received:

22.09.2020

Accepted:

18.11.2020

List of references:

Benberin VV, Akhetov AA, Narmanova OZh, Voshchenkova TA, Kulkhan TK, Kim YuA. Kardiovaskuljarnye oslozhnenija arterial’noj gipertenzii: rol’ hronicheskoj bolezni pochek. Zhurnal Nevrologіi іm. B.M. Mankovskogo. 2016;4(3):12-16. (In Russ.).
Zeltyn-Abramov EM, Zemchenkov AYu. Hypertension and chronic kidney disease: from initial to advanced stages. Diagnostic and therapeutic strategies Part 2. Renal replacement therapy (maintenance hemodialysis). Nefrologiya i dializ. 2020;22(2):237-251. (In Russ.). https://doi.org/10.28996/2618-9801-2020-2-237-251
Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, Halimi J-M, Heine GH, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verhaar MC, Wiecek A, Wuerzner G, London GM, Zoccali C. Hypertension in dialysis patients: A consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney Working Group of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2017;32(4):620-624. https://doi.org/10.1093/ndt/gfw433
Chazova IE, Zhernakova YuV. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. (In Russ.). https://doi.org/10.26442/2075082X.2019.1.190179
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. https://doi.org/10.1016/j.jacc.2017.11.006
Kazakova IA, Ievlev EN. Study of the quality of life and severity of depression in patients with arterial hypertension, receiving treatment with programmed hemodialysis. Mezhdunarodnyj zhurnal serdtsa i sosudistykh zabolevanij. 2017;5(14):19-28. (In Russ.).
Kazakova IA, Ievlev EN. Electrophoretic mobility of erythrocytes in patients with chronic renal disease of 5th dialysis stage with different level of arterial pressure. Therapy. 2019;5-2(28):30-35. (In Russ.). https://doi.org/10.18565/therapy.2019.2.30-35
Trusov VV, Aksenov KV. Vliyanie agonista imidazolinovykh retseptorov moksonidina na sostoyanie mikrotsirkulyatsii i funktsiyu pochek u bol’nykh arterial’noj gipertoniej s sakharnym diabetom 2-go tipa. Kardiologiya. 2003;43(9):44-48. (In Russ.).
Baranova EI, Polyakova EA. Antihypertensive therapy in patients with prediabetes and diabetes mellitus type 2. Therapy. 2016;2(6):53-62. (In Russ.).
Chubenko EA, Belyaeva OD, Bazhenova EA, Nifontov SE, Berkovich OA, Baranova EI. Moxonidine in metabolic syndrome. Arterial Hypertension. 2014;20(2):128-135. (In Russ.).
Ostroumova OD, Zykova AA. Renoprotection With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine. Kardiologiya. 2016;56(10):72-79. https://doi.org/10.18565/cardio.2016.10.72-79
Hiremath B, Gandigawad P. Effects of selective imidazolin-1 receptor agonists’ vs dihydropiridine calcium channel blockers on insulin resistance in patients of hypertension with metabolic syndrome: a meta-analysis of randomized controlled trials. Int J Basic Clin Pharmacol. 2016;5(2):394-401. https://doi.org/10.18203/2319-2003.ijbcp20160751
Shilova EV, Zadionchenko VS, Sviridova AA, Adasheva TV, Suvorova SS. Primenenie agonista imidazolinovykh retseptorov moksonidina u bol’nykh arterial’noj gipertoniej v sochetanii s khronicheskimi obstruktivnymi zabolevaniyami legkikh. Kardiovaskulyarnaya terapiya i profilaktika. 2002;3:19-24. (In Russ.).
Santos M, Shah AM. Alterations in cardiac structure and function in hypertension. Curr Hypertens Rep. 2014;16(5):428. https://doi.org/10.1007/s11906-014-0428-x
Bogatyreva MM-B. Severity of left ventricular hypertrophy in patients with end-stage chronic kidney disease according to echocardiography and autopsy data. Cardiovascular Therapy and Prevention. 2019;18(1):35. (In Russ.).
Borodulina EO, Shutov AM, Serov VA. Blood pressure variability and left ventricular hypertrophy in hemodialysis patients. Nefrologiya i dializ. 2018; 20(1):56-63. https://doi.org/10.28996/1680-4422-2018-1-56-63
Özel E, Taştan A, Öztürk A, Özcan E. Relationship between Sympathetic Overactivity and Left Ventricular Hypertrophy in Resistant Hypertension. Hellenic J Cardiol. 2015;56(6):501-506. https://doi.org/10.1016/j.amjcard.2015.01.07
Di Daniele N, De Francesco M, Violo L, Spinelli A, Simonetti G. Renal sympathetic nerve ablation for the treatment of diffi cult-to-control or refractory hypertension in a haemodialysis patient. Nephrol Dial Transplant. 2012;27(4):1689-1690. https://doi.org/10.1093/ndt/gfs044
Janssen BJA, Lukoshkova EV, Head GA. Sympathetic modulation of renal blood flow by rilmenidine and captopril: central vs. peripheral effects. Am J Physiol. 2002;282(1):113-123.
Tsyrlin VA, Pliss MG, Kuzmenko NV. Vegetotropnyj i emotsional’no-povedencheskij effekty moksonidina u normotenzivnykh krys. Translyatsionnaya meditsina. 2020;7(2):65-72. (In Russ.).
Kirichenko LL, Kolesnikova KO, Sharandak AP, Tseka OS, Korolev AP. Agonisty imidazolinovykh retseptorov i gipertrofiya miokarda levogo zheludochka. Kardiovaskulyarnaya terapiya i profilaktika. 2005;4(2):95-98. (In Russ.).
Mukkadam-Daher S, Gutkowska J. Imidazoline receptors in the heart: a novel target and a novel mechanism of action that involves atrial natriuretic peptides. Braz J Med Biol Res. 2004;37(8):1239-1245.
Vasilieva IA, Smirnov AV. Evaluation of quality of life in hemodialysis patients using the KDQOL-SFTM questionnaire. Nefrologiya. 2017;21(4):55-60. (In Russ.). https://doi.org/10.24884/1561-6274-2017-21-4-55-60
Mikhailova LV, Gorenshtein TA, Vilms AL, Ramazanova VR. Pokazateli kachestva zhizni u bol’nykh s terminal’noj stadiej khronicheskoj bolezni pochek na gemodialize. Vestnik Baltijskogo federal’nogo universiteta im. I. Kanta. Seriya: Estestvennye i meditsinskie nauki. 2019;2:88-97. (In Russ.).
Gulov MK, Abdulloev SM, Rofiev KhK. Kachestvo zhizni u pacientov, stradajushhih hronicheskoj bolezn’ju pochek. Rossijskij mediko-biologicheskij vestnik im. akad. I.P. Pavlova. 2018;26(4):493-499. (In Russ.).
Tully Ph, Baker R. Depression, anxiety, and cardiac morbidity outcomes after coronary artery bypass surgery: a contemporary and practical review. J Geriat Cardiol. 2012;9:197-208.
Rustamova FE, Musaev AT, Magauin EK, Bazarbek RU, Rakhmatulla UA, Ezhikova AA, Kabdulashov KS, Magauina AK, Sultamuratova FB, Akhmadi BD. Sutochnoe monitorirovanie arterial’nogo davleniya i sostoyaniya serdechno-sosudistoj sistemy u bol’nykh s arterial’noj gipertenziej na fone terapii. Mezhdunarodnyj zhurnal prikladnykh i fundamental’nykh issledovanij. 2017;5:257-262. (In Russ.).

Close metadata